Literature DB >> 6927044

Simplified toxicologic monitoring of adriamycin, its major metabolites and nogalamycin by reverse-phase high pressure liquid chromatography, Part I: Analytical techniques for isolated human plasma.

A J Quattrone, D F Ranney.   

Abstract

A simplified method is presented for routine toxicologic analysis of the antineoplastic drug, adriamycin, and its major metabolites in human plasma. This method employs a single solvent extraction of plasma using an acetonitrile-aqueous NaOH mixture, followed by reverse-phase isocratic high pressure liquid chromatographic (HPLC) analysis. Recoveries of greater than 95% are obtained for adriamycin and its two major derivatives over the range of concentration: 0.2 to 8.0 nmol/mL of plasma. This method of drug and metabolite isolation and HPLC analysis from human plasma provides an efficient and accurate approach to the individualized toxicologic monitoring of adriamycin pharmacokinetics and metabolism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6927044     DOI: 10.1093/jat/4.1.12

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  4 in total

1.  A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.

Authors:  W Bolanowska; T Gessner; H Preisler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.

Authors:  D E Brenner; S Galloway; J Cooper; R Noone; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 3.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

4.  HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids.

Authors:  C M Camaggi; R Comparsi; E Strocchi; F Testoni; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.